-
Je něco špatně v tomto záznamu ?
Preventing long-term disability in CIDP: the role of timely diagnosis and treatment monitoring in a multicenter CIDP cohort
P. Quint, CB. Schroeter, F. Kohle, M. Öztürk, A. Meisel, G. Tamburrino, AK. Mausberg, F. Szepanowski, AM. Afzali, K. Fischer, C. Nelke, S. Räuber, J. Voth, L. Masanneck, A. Willison, A. Vogelsang, B. Hemmer, A. Berthele, M. Schroeter, HP....
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články, multicentrická studie
NLK
ProQuest Central
od 1997-04-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2000-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1997-04-01 do Před 1 rokem
- MeSH
- chronická zánětlivá demyelinizační polyneuropatie * diagnóza terapie farmakoterapie MeSH
- dospělí MeSH
- intravenózní imunoglobuliny terapeutické užití aplikace a dávkování MeSH
- kohortové studie MeSH
- lidé středního věku MeSH
- lidé MeSH
- prednisolon terapeutické užití aplikace a dávkování MeSH
- progrese nemoci MeSH
- retrospektivní studie MeSH
- senioři MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
BACKGROUND: Chronic inflammatory demyelinating polyneuropathy (CIDP) is an inflammatory disease affecting the peripheral nerves and the most frequent autoimmune polyneuropathy. Given the lack of established biomarkers or risk factors for the development of CIDP and patients' treatment response, this research effort seeks to identify potential clinical factors that may influence disease progression and overall treatment efficacy. METHODS: In this multicenter, retrospective analysis, we have screened 197 CIDP patients who presented to the University Hospitals in Düsseldorf, Berlin, Cologne, Essen, Magdeburg and Munich between 2018 and 2022. We utilized the respective hospital information system and examined baseline data with clinical examination, medical letters, laboratory results, antibody status, nerve conduction studies, imaging and biopsy findings. Aside from clinical baseline data, we analyzed treatment outcomes using the Standard of Care (SOC) definition, as well as a comparison of an early (within the first 12 months after manifestation) versus late (more than 12 months after manifestation) onset of therapy. RESULTS: In terms of treatment, most patients received intravenous immunoglobulin (56%) or prednisolone (39%) as their first therapy. Patients who started their initial treatment later experienced a worsening disease course, as reflected by a significant deterioration in their Inflammatory Neuropathy Cause and Treatment (INCAT) leg disability score. SOC-refractory patients had worse clinical outcomes than SOC-responders. Associated factors for SOC-refractory status included the presence of fatigue as a symptom and alcohol dependence. CONCLUSION: Timely diagnosis, prompt initiation of treatment and careful monitoring of treatment response are essential for the prevention of long-term disability in CIDP and suggest a "hit hard and early" treatment paradigm.
Brain and Mind Center University of Sydney 94 Mallett St Sydney Australia
Center for Behavioral Brain Sciences Otto von Guericke University 39106 Magdeburg Germany
Center for Translational Neuro and Behavioral Sciences University of Duisburg Essen Essen Germany
Department of Neurology Essen University Hospital University Duisburg Essen Essen Germany
Department of Neurology Otto von Guericke University 39120 Magdeburg Germany
Department of Neurology Palacky University Olomouc Nová Ulice 779 00 Olomouc Czech Republic
German Center for Neurodegenerative Diseases 39120 Magdeburg Germany
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24019112
- 003
- CZ-PrNML
- 005
- 20241024111554.0
- 007
- ta
- 008
- 241015s2024 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00415-024-12548-1 $2 doi
- 035 __
- $a (PubMed)38990346
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Quint, Paula $u Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Moorenstr. 5, 40225, Duesseldorf, Germany $1 https://orcid.org/0009000714631961
- 245 10
- $a Preventing long-term disability in CIDP: the role of timely diagnosis and treatment monitoring in a multicenter CIDP cohort / $c P. Quint, CB. Schroeter, F. Kohle, M. Öztürk, A. Meisel, G. Tamburrino, AK. Mausberg, F. Szepanowski, AM. Afzali, K. Fischer, C. Nelke, S. Räuber, J. Voth, L. Masanneck, A. Willison, A. Vogelsang, B. Hemmer, A. Berthele, M. Schroeter, HP. Hartung, M. Pawlitzki, S. Schreiber, M. Stettner, U. Maus, SG. Meuth, F. Stascheit, T. Ruck
- 520 9_
- $a BACKGROUND: Chronic inflammatory demyelinating polyneuropathy (CIDP) is an inflammatory disease affecting the peripheral nerves and the most frequent autoimmune polyneuropathy. Given the lack of established biomarkers or risk factors for the development of CIDP and patients' treatment response, this research effort seeks to identify potential clinical factors that may influence disease progression and overall treatment efficacy. METHODS: In this multicenter, retrospective analysis, we have screened 197 CIDP patients who presented to the University Hospitals in Düsseldorf, Berlin, Cologne, Essen, Magdeburg and Munich between 2018 and 2022. We utilized the respective hospital information system and examined baseline data with clinical examination, medical letters, laboratory results, antibody status, nerve conduction studies, imaging and biopsy findings. Aside from clinical baseline data, we analyzed treatment outcomes using the Standard of Care (SOC) definition, as well as a comparison of an early (within the first 12 months after manifestation) versus late (more than 12 months after manifestation) onset of therapy. RESULTS: In terms of treatment, most patients received intravenous immunoglobulin (56%) or prednisolone (39%) as their first therapy. Patients who started their initial treatment later experienced a worsening disease course, as reflected by a significant deterioration in their Inflammatory Neuropathy Cause and Treatment (INCAT) leg disability score. SOC-refractory patients had worse clinical outcomes than SOC-responders. Associated factors for SOC-refractory status included the presence of fatigue as a symptom and alcohol dependence. CONCLUSION: Timely diagnosis, prompt initiation of treatment and careful monitoring of treatment response are essential for the prevention of long-term disability in CIDP and suggest a "hit hard and early" treatment paradigm.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a chronická zánětlivá demyelinizační polyneuropatie $x diagnóza $x terapie $x farmakoterapie $7 D020277
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a progrese nemoci $7 D018450
- 650 _2
- $a intravenózní imunoglobuliny $x terapeutické užití $x aplikace a dávkování $7 D016756
- 650 _2
- $a kohortové studie $7 D015331
- 650 _2
- $a prednisolon $x terapeutické užití $x aplikace a dávkování $7 D011239
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Schroeter, Christina B $u Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Moorenstr. 5, 40225, Duesseldorf, Germany
- 700 1_
- $a Kohle, Felix $u Department of Neurology, Faculty of Medicine, University of Cologne and University Hospital of Cologne, Cologne, Germany
- 700 1_
- $a Öztürk, Menekse $u Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Moorenstr. 5, 40225, Duesseldorf, Germany
- 700 1_
- $a Meisel, Andreas $u Department of Neurology and Experimental Neurology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany $u Neuroscience Clinical Research Center, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany
- 700 1_
- $a Tamburrino, Giuliano $u Department of Neurology, Faculty of Medicine, University of Cologne and University Hospital of Cologne, Cologne, Germany
- 700 1_
- $a Mausberg, Anne K $u Department of Neurology, Essen University Hospital, University Duisburg-Essen, Essen, Germany $u Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University of Duisburg-Essen, Essen, Germany
- 700 1_
- $a Szepanowski, Fabian $u Department of Neurology, Essen University Hospital, University Duisburg-Essen, Essen, Germany $u Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University of Duisburg-Essen, Essen, Germany
- 700 1_
- $a Afzali, Ali Maisam $u Department of Neurology, Klinikum Rechts der Isar, Technical University Munich School of Medicine and Health, Ismaninger Str. 22, 81675, Munich, Germany $u Institute for Experimental Neuroimmunology, Technical University of Munich School of Medicine and Health, Munich, Germany
- 700 1_
- $a Fischer, Katinka $u Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Moorenstr. 5, 40225, Duesseldorf, Germany
- 700 1_
- $a Nelke, Christopher $u Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Moorenstr. 5, 40225, Duesseldorf, Germany
- 700 1_
- $a Räuber, Saskia $u Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Moorenstr. 5, 40225, Duesseldorf, Germany
- 700 1_
- $a Voth, Jan $u Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Moorenstr. 5, 40225, Duesseldorf, Germany
- 700 1_
- $a Masanneck, Lars $u Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Moorenstr. 5, 40225, Duesseldorf, Germany
- 700 1_
- $a Willison, Alice $u Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Moorenstr. 5, 40225, Duesseldorf, Germany
- 700 1_
- $a Vogelsang, Anna $u Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Moorenstr. 5, 40225, Duesseldorf, Germany
- 700 1_
- $a Hemmer, Bernhard $u Department of Neurology, Klinikum Rechts der Isar, Technical University Munich School of Medicine and Health, Ismaninger Str. 22, 81675, Munich, Germany $u Munich Cluster for Systems Neurology (SyNergy), 81377, Munich, Germany
- 700 1_
- $a Berthele, Achim $u Department of Neurology, Klinikum Rechts der Isar, Technical University Munich School of Medicine and Health, Ismaninger Str. 22, 81675, Munich, Germany
- 700 1_
- $a Schroeter, Michael $u Department of Neurology, Faculty of Medicine, University of Cologne and University Hospital of Cologne, Cologne, Germany
- 700 1_
- $a Hartung, Hans-Peter $u Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Moorenstr. 5, 40225, Duesseldorf, Germany $u Brain and Mind Center, University of Sydney, 94 Mallett St, Sydney, Australia $u Department of Neurology, Palacky University Olomouc, Nová Ulice, 779 00, Olomouc, Czech Republic
- 700 1_
- $a Pawlitzki, Marc $u Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Moorenstr. 5, 40225, Duesseldorf, Germany
- 700 1_
- $a Schreiber, Stefanie $u Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Moorenstr. 5, 40225, Duesseldorf, Germany $u Department of Neurology, Otto-von-Guericke University, 39120, Magdeburg, Germany $u German Center for Neurodegenerative Diseases (DZNE), 39120, Magdeburg, Germany $u Center for Behavioral Brain Sciences (CBBS), Otto-von-Guericke University, 39106, Magdeburg, Germany
- 700 1_
- $a Stettner, Mark $u Department of Neurology, Essen University Hospital, University Duisburg-Essen, Essen, Germany $u Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University of Duisburg-Essen, Essen, Germany
- 700 1_
- $a Maus, Uwe $u Department of Orthopaedics and Trauma Surgery, Medical Faculty, Heinrich Heine University Duesseldorf, Moorenstr. 5, 40225, Duesseldorf, Germany
- 700 1_
- $a Meuth, Sven G $u Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Moorenstr. 5, 40225, Duesseldorf, Germany
- 700 1_
- $a Stascheit, Frauke $u Department of Neurology and Experimental Neurology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany $u Neuroscience Clinical Research Center, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany
- 700 1_
- $a Ruck, Tobias $u Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Moorenstr. 5, 40225, Duesseldorf, Germany. Tobias.Ruck@med.uni-duesseldorf.de
- 773 0_
- $w MED00002835 $t Journal of neurology $x 1432-1459 $g Roč. 271, č. 9 (2024), s. 5930-5943
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38990346 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20241024111548 $b ABA008
- 999 __
- $a ok $b bmc $g 2201750 $s 1231085
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 271 $c 9 $d 5930-5943 $e 20240711 $i 1432-1459 $m Journal of neurology $n J Neurol $x MED00002835
- LZP __
- $a Pubmed-20241015
